TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04124887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate
Description: Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol-coated calcium and phosphate
Description: Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
Study: NCT02151877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
Study: NCT01323712

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D Cholecalciferol
Description: Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
Study: NCT03954522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interview
Description: Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed
Study: NCT03705078

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transjugular Portosytemic Shunt (TIPS)
Description: The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: glue obliteration
Description: The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
Study: NCT03780829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: intermittent cycles of normoxia-hypoxia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: intermittent cycles of normoxia-hypoxia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: hypoxia
Description: intermittent cycles of normoxia-hypoxia

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham hypoxia
Description: intermittent cycles of sham hypoxia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: NMDA agonist treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham-NMDA agonist
Description: sham-NMDA agonist treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: bimanual massed practice training
Study: NCT01811485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
Study: NCT01490008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veregen
Description: Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
Study: NCT03780829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: bimanual massed practice training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise training
Description: bimanual massed practice training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exercise training
Description: bimanual massed practice training
Study: NCT03769506

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASP-1929 Photoimmunotherapy
Description: Use of ASP-1929 PIT therapy
Study: NCT02295189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: anti-inflammatory injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: anti-inflammatory injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: corticosteroid injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: corticosteroid injection
Study: NCT02673216

Intervention type: OTHER
Intervention: No intervention
Study: NCT03769506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice SOC
Description: docetaxel, cetuximab, methotrexate, paclitaxel
Study: NCT02871219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01490008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals
Study: NCT02976636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral therapy
Description: Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy
Description: Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting training
Description: Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
Study: NCT01942668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Study: NCT04422912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSG3-CAART or CABA-201
Description: Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201.
Study: NCT04540224

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-Cytometric analysis
Description: Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
Study: NCT02871219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT03304639

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03085407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early cholecystectomy
Description: cholecystectomy was done within 48 after admission

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: delayed cholecystectomy
Description: cholecystectomy was done after 30 days after randomization
Study: NCT04200287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online decision aid tool
Description: The decision aid intervention will be presented via a website
Study: NCT03358433

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT03304639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04233645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-minute educational video
Description: The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The groups will be given a standard scripted verbal and identical written instructions as per usual care.
Study: NCT03304639

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT02777398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Quadrant Channel Surgery
Description: Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
Study: NCT02339571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT04233645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The groups will be given a standard scripted verbal and identical written instructions as per usual care.
Study: NCT02339571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT04380168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified pec11 trunk block
Description: Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified pec11 trunk block
Description: Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified pec11 trunk block
Description: Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
Study: NCT04077983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined therapy using nab-paclitaxel and gemcitabine chemotherapy
Description: 1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses.
Study: NCT02777398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Open Surgery
Description: Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
Study: NCT00497913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study: NCT03481322

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cooked diet with controlled amount of salt
Description: Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cooked diet with controlled amount of salt
Description: Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
Study: NCT01218204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: OTHER
Intervention: 80mg atorvastatin
Description: 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg atorvastatin
Description: 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80mg atorvastatin
Description: 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263 Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263 Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg GSK1292263
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg GSK1292263
Description: 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg GSK1292263
Description: 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg GSK1292263
Description: 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg GSK1292263
Description: 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg GSK1292263
Description: 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg ezetimibe
Description: 10mg

Intervention type: OTHER
Group type: OTHER
Intervention: Washout
Description: No interventions - washout period
Study: NCT01141907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Self Care Support
Description: The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual heart failure care
Description: Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
Study: NCT03090113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection
Description: intravenous drip
Study: NCT02339571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00497913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Study: NCT03349801

Intervention type: OTHER
Intervention: No intervention
Description: According to clinical practice.

Intervention type: OTHER
Intervention: No intervention
Description: According to clinical practice.

Intervention type: OTHER
Intervention: No intervention
Description: According to clinical practice.
Study: NCT01942668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03090113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: intravenous drip
Study: NCT00585819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reproduce breathing cycle utilizing spirometry
Description: reproduce breathing cycle utilizing spirometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freebreathing in Body fix mold
Description: Freebreathing in Body fix mold
Study: NCT02852408

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Study: NCT04675840

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted hysterectomy
Description: Robotic-assisted surgery
Study: NCT03905603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: ACTH (Cosyntropin) 250 mcg will be given once during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: rhCG (Ovidrel) 250 mcg will be given once during the study.
Study: NCT02759328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ training
Description: Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
Study: NCT01987505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg will be injected subcutaneously (SC).
Study: NCT03795987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.